Your body sends signals when its reproductive machinery is changing gears, and FSH (follicle-stimulating hormone) is one of the loudest. When the ovaries or testes start producing less of their key hormones, the pituitary gland compensates by pumping out more FSH, like a thermostat cranking up the heat when a room gets cold. A rising FSH level can reveal declining fertility, approaching menopause, or testicular problems years before you notice anything is wrong.
Beyond reproduction, FSH levels are tied to bone health, metabolic risk, and cardiovascular changes. Whether you are trying to conceive, wondering if perimenopause has started, investigating unexplained symptoms, or simply want a clearer picture of your hormonal health, this number provides information that standard blood panels do not include.
FSH is a protein hormone made by specialized cells in the pituitary gland, a pea-sized structure at the base of your brain. It belongs to a family of signaling hormones called gonadotropins that communicate between the brain and the reproductive organs. The pituitary releases FSH in response to a master signal from the hypothalamus (a region of the brain that coordinates hormonal activity) called GnRH, or gonadotropin-releasing hormone.
In women, FSH tells the ovaries to develop follicles, the small fluid-filled sacs that each contain an egg. As follicles mature, they produce estrogen, which signals the pituitary to ease off on FSH production. This feedback loop keeps the system balanced. In men, FSH acts on Sertoli cells in the testes, the support cells that nurture developing sperm. The testes produce inhibin B, a protein that tells the pituitary how much FSH is enough.
When this feedback loop weakens, whether because the ovaries are running low on eggs or the testes are not responding normally, FSH rises. That rise is the pituitary's attempt to squeeze more output from glands that are producing less. This is why elevated FSH is a window into declining reproductive capacity: the number goes up precisely because the system is struggling.
In women, elevated FSH most commonly reflects diminished ovarian reserve, meaning fewer eggs remain available. An early follicular phase FSH above 10 mIU/mL (measured on cycle days 2 through 4) suggests the ovaries are working harder than expected to develop follicles. Levels above 15 mIU/mL indicate significantly decreased reserve, and levels above 20 mIU/mL are associated with near-zero pregnancy probability in fertility treatment settings.
Very high FSH, often above 40 IU/L with low estradiol, points to primary ovarian insufficiency (POI), a condition where ovarian function fails before age 40. During the natural transition to menopause, FSH rises steadily, typically exceeding 25 IU/L in the late stages. After menopause, levels commonly range from 40 to 70 mIU/mL or higher.
In men, high FSH signals primary testicular failure. The testes may be damaged by chemotherapy, radiation, infection, excessive alcohol use, or a genetic condition like Klinefelter syndrome. In children, elevated FSH alongside high LH can indicate precocious puberty, the onset of sexual development earlier than expected (before age 8 in girls, age 9 in boys).
Low FSH points upstream, to a problem with the pituitary gland or the hypothalamus rather than the reproductive organs themselves. In women, this pattern appears in functional hypothalamic amenorrhea, where chronic stress, excessive exercise, or very low body weight essentially shuts down the brain's reproductive signaling. Low FSH with low estradiol and absent periods is the hallmark.
Pituitary tumors, infiltrative diseases, or genetic conditions affecting GnRH production can also drive FSH too low. In men, low FSH alongside low testosterone suggests secondary hypogonadism, a condition originating in the brain's hormonal control centers rather than in the testes. In children, low FSH combined with low LH may explain delayed puberty.
FSH appears to have effects on bone that go beyond its role in reproduction. A prospective study of older adults in Iceland found that each standard-deviation increase in FSH was associated with a 24% higher risk of hip fracture, and this association held even after accounting for estradiol, testosterone, and sex hormone-binding globulin levels. That last point matters: it suggests FSH itself, not just the estrogen decline that usually accompanies rising FSH, may contribute to bone loss.
A cross-sectional analysis of 675 postmenopausal women from the Women's Health Initiative found that women in the highest FSH group had about 3 times the odds of low bone mass or osteoporosis at the femoral neck compared to those in the lowest group, after adjusting for age, hormone therapy, and diabetes. The researchers estimated that FSH accounted for roughly 70% of the relationship between estradiol and bone mineral density, suggesting FSH may be a more direct driver of bone loss than previously thought.
The relationship between FSH and metabolic disease in postmenopausal women runs in a direction many people find surprising: higher FSH appears to be associated with lower diabetes risk, not higher. A study of 588 postmenopausal Finnish women found that those with FSH above 50 IU/L had about half the odds of having diabetes compared to those with lower FSH. Each one-unit increase in FSH was linked to a 1.9% lower diabetes risk.
A larger Chinese study of over 6,000 postmenopausal women reinforced this pattern. Women in the lowest FSH group had about 3 times the odds of diabetes compared to those in the highest group. A separate five-year prospective study in Polish women found that each standard-deviation decrease in FSH was associated with a threefold increase in the risk of developing impaired fasting glucose, and a fivefold increase in the risk of insulin resistance or diabetes.
These findings do not mean that high FSH protects against diabetes. The association likely reflects the fact that higher body fat suppresses FSH, and higher body fat also drives insulin resistance. Women with lower FSH may have more metabolic risk factors. Still, FSH adds a useful signal when read alongside metabolic markers like fasting glucose, HbA1c, and insulin.
The cardiovascular picture is mixed and depends on sex. In postmenopausal women, higher FSH has been associated with lower predicted cardiovascular risk. A study of 2,658 postmenopausal Chinese women found that each standard-deviation increase in FSH was associated with about 35% lower odds of high predicted 10-year cardiovascular risk, after adjusting for age, estradiol, BMI, and lipids. A separate study of 587 postmenopausal Finnish women found that higher FSH was linked to less thickening of the carotid artery walls, an early marker of atherosclerosis.
In men, the story is different. Multiple large studies, including the Framingham Heart Study (254 elderly men), the Concord study (1,705 men over 70), and a Danish population study (5,350 men followed up to 30 years), found no significant association between FSH and cardiovascular disease or mortality in men. These findings suggest FSH's cardiovascular relevance is largely specific to postmenopausal women.
FSH levels depend heavily on age, sex, and, in women, where you are in the menstrual cycle or menopausal transition. Different labs use different assays, and a 2018 survey of 117 U.S. laboratories found that the upper limit of normal for FSH in men ranged from 7.9 to 20.0 IU/L depending on the lab. Always compare your results within the same laboratory over time.
| Tier | Range (mIU/mL, cycle days 2 to 4) | What It Suggests |
|---|---|---|
| Adequate Reserve | Below 10 | Normal ovarian reserve for your age group |
| Borderline | 10 to 15 | Possible early decline in ovarian reserve; consider retesting next cycle |
| Diminished Reserve | Above 15 | Significantly decreased reserve with reduced pregnancy probability |
| Severely Diminished | Above 20 | Very low likelihood of pregnancy with fertility treatment |
These tiers are drawn from fertility medicine guidelines and apply specifically to early follicular phase measurements. FSH increases by roughly 0.11 IU/L per year of age in reproductive-age women, so a level that looks borderline at 30 may be typical at 42. Your lab may use different assays and cutpoints. Compare results within the same lab over time for the most meaningful trend.
| Stage | Typical FSH Range (mIU/mL) | What It Suggests |
|---|---|---|
| Late Perimenopause | Above 25 | Transition to menopause is well underway |
| Around Final Period | Around 34 | Near the end of reproductive cycling |
| Postmenopausal (Plateau) | Around 54 to 70+ | Stable postmenopausal levels |
During perimenopause, FSH can swing dramatically between cycles, rising to postmenopausal levels in one cycle and falling back to fertile-range levels in the next. A single reading during this transition can be misleading.
| Tier | Range (IU/L) | What It Suggests |
|---|---|---|
| Normal (Young Adults) | 1.3 to 8.4 | Healthy testicular function |
| Borderline Elevated | 8.5 to 12 | May warrant investigation if fertility is a concern |
| Elevated | Above 12 | Suggests primary testicular dysfunction; further evaluation recommended |
FSH increases gradually with age in men, rising from around 4.0 mIU/mL in younger men to around 16.0 mIU/mL in older men. In the context of male infertility, FSH above the 95th percentile (12.1 mIU/mL) had the highest predictive value for identifying spermatogenic failure.
The SWAN study, which followed women through the menopausal transition, found that African American women had higher FSH concentrations than Caucasian women, while Chinese and Japanese women had similar FSH levels to Caucasian women despite having lower estradiol levels. These differences persisted after accounting for menopausal status and BMI, so the same FSH number may carry slightly different significance depending on your ethnic background.
A single FSH reading is a snapshot, not the full picture. In premenopausal women, FSH is notoriously variable from one cycle to the next. One study found that in premenopausal women, a single FSH measurement had a reliability coefficient of just 0.09, meaning the test captured less than 10% of the true signal versus noise. High cycle-to-cycle variability itself is a sign of declining ovarian reserve, so inconsistency between readings is actually informative.
In postmenopausal women and men, the picture is more stable. A single measurement in postmenopausal women had a reliability coefficient of 0.70, meaning one reading is usually representative. The within-person variability in men is about 8%, making serial readings fairly consistent.
For premenopausal women tracking ovarian reserve, get at least two early follicular phase readings in separate cycles before drawing conclusions. If your first result is borderline or elevated, retest next cycle. For postmenopausal women and men, a baseline reading followed by annual retesting is sufficient unless results are abnormal. If you are making changes to address an abnormal result (such as weight loss or medication adjustment), retest in 3 to 6 months to see whether the number is moving.
The biggest source of misleading FSH results in premenopausal women is testing on the wrong day of the menstrual cycle. FSH peaks just before ovulation, so a mid-cycle blood draw will produce a reading that looks elevated even when ovarian reserve is perfectly normal. Always test on cycle days 2 through 4, and always measure estradiol at the same time. If estradiol is elevated on the same draw, it may be artificially suppressing FSH and masking a true decline in reserve.
Critical illness and major surgery can suppress FSH by 62% to 74% within 24 hours, and this suppression can persist for days to weeks. If you have been hospitalized recently, wait until you have fully recovered before testing. Severe caloric restriction (multi-day fasting) can reduce FSH modestly in men, around 13%, though the effect is smaller than for other reproductive hormones.
Body weight affects FSH in a pattern that can confuse interpretation: higher BMI is associated with lower FSH. This means that in overweight or obese women approaching menopause, FSH may stay deceptively low, masking the transition. The relationship also means that weight loss can cause FSH to rise, which reflects improved hormonal signaling rather than worsening ovarian function.
Biotin supplements, commonly taken for hair and nail health, can interfere with many immunoassay-based hormone tests, including FSH. Stop biotin at least 72 hours before your blood draw. Rare cases of falsely elevated FSH due to autoantibody interference with lab assays have also been reported, so if your result seems inconsistent with your clinical picture, consider retesting on a different assay platform.
Evidence-backed interventions that affect your FSH level
FSH is best interpreted alongside these tests.